Symbiotec Pharmalab IPO

No current grey market premium reading is being quoted for the Symbiotec Pharmalab Limited IPO — the issue has listed and the grey market stops quoting once shares trade on the exchange. The day-wise history on this page shows every reading we recorded. GMP is an unofficial, unregulated datapoint reported by third parties — not a price, a prediction, or investment advice.

No. The grey market is an informal, over-the-counter market between private dealers that is not operated or supervised by NSE, BSE or SEBI. No trade settles through a clearing corporation and no dealer is obliged to honour a quote, so the premium can change sharply within a day or disappear after bidding closes.

The premium is checked about every 20 minutes from third-party grey-market reporters while the issue is live. The history table adds a row only when the premium changes, with the date and time it changed, how much it moved and the listing price it implies.

As of 27 Aug, 7:05 pm the Symbiotec Pharmalab Limited IPO is subscribed 71.26× overall: QIB 172.03×, non-institutional 73.63× and retail 12.96×. Figures are the exchange's consolidated demand across NSE and BSE.

The retail portion is subscribed 12.96× as of 27 Aug, 7:05 pm. Retail applications are those up to ₹2,00,000 at the cut-off price.

NSE and BSE publish the category-wise bids for every open issue during bidding hours. This page reads that feed and shows the QIB, NII and retail book, plus one row per day so the build-up over the issue can be compared.

Overall subscription at the end of each bidding day — day 1 (24 August 2026): 0.8×, day 2 (25 August 2026): 1.85×, day 3 (26 August 2026): 5.3×, day 4 (27 August 2026): 71.26× — from the exchange feed. The day-wise table on this page breaks each day into QIB, non-institutional and retail.

Subscription of 2× means bids were received for twice the number of shares offered in that category. When a category is oversubscribed, allotment in it is decided by the registrar under the basis-of-allotment rules — retail by lottery for the minimum lot, for example.

Allotment for the Symbiotec Pharmalab Limited IPO is expected to be finalised on 28 August 2026, the trading day after the issue closes on 27 August 2026. Under SEBI's T+3 timeline refunds and demat credit follow on 31 August 2026 and the shares list on 1 September 2026. Dates are tentative until the registrar and exchange confirm them.

Allotment is decided and published by the registrar, MUFG Intime India Private Limited (Formerly Link Intime India Private Limited) — not by the exchange and not by alphave. Open the registrar's IPO allotment page, choose the issue, and enter your PAN, application number or DP ID / client ID. Your bank will also show the blocked amount released if shares were not allotted.

The registrar to the Symbiotec Pharmalab Limited IPO is MUFG Intime India Private Limited (Formerly Link Intime India Private Limited). The registrar processes applications, finalises the basis of allotment with the exchange, and handles refunds.

The amount blocked in your bank account under ASBA or the UPI mandate is released, normally on the day allotment is finalised or the next working day. No shares are credited and nothing further is needed from you.

Bidding for the Symbiotec Pharmalab Limited IPO opens on 24 August 2026 and closes on 27 August 2026. Exchange bidding runs from 10:00 am to 5:00 pm IST on each day; UPI mandates must be accepted by 5:00 pm on the closing day, and brokers may stop taking bids somewhat earlier.

The shares are scheduled to list on 1 September 2026 on NSE. Trading starts at 10:00 am IST after the special pre-open session that discovers the listing price.

Applications are made through a broker's app or a bank's net banking using ASBA, or by UPI mandate, between 24 August 2026 and 27 August 2026. The amount is only blocked, not debited, until allotment. Retail bids of up to ₹2,00,000 are usually placed at the cut-off price (₹988); a UPI mandate must be approved by 5:00 pm on the closing day.

27 August 2026 is the last day of bidding. Allotment is then expected on 28 August 2026, refunds and demat credit on 31 August 2026, and listing on 1 September 2026 — tentative until confirmed.

The Symbiotec Pharmalab Limited IPO price band is ₹988 to ₹988 per share. Applications are made at the cut-off price, which is the upper end of the band.

One lot is 15 shares, so a single application at the ₹988 cut-off costs ₹14,820. Retail investors can apply for up to 13 lots within the ₹2,00,000 retail limit.

₹14,820 — one lot of 15 shares at ₹988. Bids in the non-institutional category start above ₹2,00,000 and are made in multiples of the lot.

Symbiotec Pharmalab Limited is a mainboard issue listing on NSE. The lead manager is JM Financial Limited.

The issue size is ₹1,850.99 crore, of which ₹150 crore is a fresh issue and ₹1,607 crore an offer for sale by existing shareholders.

Symbiotec Pharmalab Limited reported revenue of ₹869.15 crore in FY2026, as restated in its offer document. The table on this page shows each reported year.

Symbiotec Pharmalab Limited reported a profit after tax of ₹109.9 crore in FY2026. Earlier years are in the table above.

From the restated financial statements in the company's draft and final offer documents filed with SEBI and the exchange. alphave reports them as filed, in ₹ crore, and does not publish a valuation or a view on the issue.

Before the issue the promoter and promoter group hold 34.47% of Symbiotec Pharmalab Limited. An unlisted company has no public shareholders; the public holding is created by the shares sold in this IPO.

The pre-issue register is the capital structure disclosed in the offer document; the post-issue pattern is the company's shareholding-pattern filing with NSE or BSE once it is published, and the offer document's disclosed post-issue register until then.

The offer document for the Symbiotec Pharmalab Limited IPO is linked on this page as filed with the exchange; SEBI and the lead managers also host it.

The Draft Red Herring Prospectus is the document a company files with SEBI before an IPO. It describes the business, the financials, the risk factors, the promoters and how the money raised will be used. The Red Herring Prospectus (RHP) is the version filed just before the issue opens, with the price band and dates added.

In Fiscals 2026, 2025 and 2024, revenue from the United States represented 13.12%, 4.02% and 8.97% of our revenue from operations. The imposition of tariffs or other anti-outsourcing legislation by the United States could adversely affect our results of operations, financial condition and cash flows We operate in a highly competitive market. We face competition both within our API manufacturing business and in our role as a CDMO, which we have recently commenced. An inability to compete effectively may adversely affect our business, results of operations, financial condition and cash flows We procure a portion of our raw material requirements from different countries, including China and the United States. Any adverse developments in these countries, or the laws governing our imports from these countries, could disrupt our raw material supply and adversely affect our results of operations, financial condition and cash flows The page lists all 8 disclosed risk factors.

The Symbiotec Pharmalab Limited shares are scheduled to list on 1 September 2026 on NSE. The listing price is discovered in a special pre-open session from 9:00 am and normal trading begins at 10:00 am IST.

Symbiotec Pharmalab Limited listed at ₹988, a gain of 0.0% on the ₹988 issue price.

On listing day the exchange runs a special pre-open session for the new stock from 9:00 am IST in which orders are collected and the listing price is discovered; continuous trading in the shares begins at 10:00 am IST.

Subscription figures are the exchange's own category-wise bids (NSE and BSE), refreshed every 5 minutes while bidding is open and frozen at the final tally after close. GMP is an unofficial grey-market indicator read about once an hour from third-party reporters, each reading timestamped. Price band, lot size, issue size, dates, registrar and lead managers are from the exchange's issue master and the offer document filed with SEBI. Financials and the shareholding pattern are as restated in the offer document; allotment is published only by the registrar, which this page links to. Anchor investor allocations, where shown, are the exchange's anchor allocation file.